The prevalence of the often disabling psychiatric diseases schizophrenia and major depressive disorder (MDD) is growing in Brazil and Mexico. Antipsychotics (older typical or newer atypical antipsychotics) are the standard of care for schizophrenia and an increasingly popular option for patients with treatment-resistant depression (TRD). In an over-genericized market of well-established key agents, the uptake of new antipsychotics is hampered by stringent budgets and market access obstacles. However, high unmet need remains for therapies with demonstrated efficacy for both conditions. In this Access & Reimbursement analysis, we discuss the current access landscape for antipsychotics in Brazil and Mexico, with a focus on atypical antipsychotics’ use in schizophrenia and TRD. Based on primary research with psychiatrists and payers in these two countries, we also analyze the future uptake of emerging therapies (e.g., Lundbeck/Otsuka’s brexpiprazole) and pinpoint the levers of and roadblocks to their success.
Clarivate’s Access & Reimbursement module for schizophrenia and MDD in Brazil and Mexico explores the prescribing patterns for current antipsychotics for these indications; the potential impact of the anticipated arrival of novel therapies; and key national, regional, and institutional market access factors that will shape the use of antipsychotics over the next two to three years. This module draws on insights from 101 surveyed psychiatrists and interviews with 6 payers in Brazil and Mexico, all of whom have influence at the institutional, regional, or national level.
Markets covered: Brazil and Mexico.
Questions Answered in This Report: